ArticleOncology letters2019
Metformin-activated AMPK regulates β-catenin to reduce cell proliferation in colon carcinoma RKO cells.
Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 38 citations in OpenAlex.
- Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial.Nature communications · 2025Trial
- Regulation of Autophagy and Metabolism in Hepatocellular Carcinoma: Involvement of Wnt-β-Catenin Pathway.Journal of cellular and molecular medicine · 2026Article
- Genetic overlap between sarcoidosis and lung cancer: a combined in silico and in vitro approach.Hereditas · 2025Article
- Article
- Transferrin promotes fatty acid oxidation and liver tumor growth through PHD2-mediated PPARα hydroxylation in an iron-dependent manner.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Role of Autophagy and AMPK in Cancer Stem Cells: Therapeutic Opportunities and Obstacles in Cancer.International journal of molecular sciences · 2024Review
- Bisbiguanide analogs induce mitochondrial stress to inhibit lung cancer cell invasion.iScience · 2024Article
- A role for β-catenin in diet-induced skeletal muscle insulin resistance.Physiological reports · 2023Article
- Progranulin is an FMRP target that influences macroorchidism but not behaviour in a mouse model of Fragile X Syndrome.Current research in neurobiology · 2023Article
- Gradual deterioration of fatty liver disease to liver cancerFrontiers in oncology · 2023Article
- AMPK activator decelerates osteoarthritis development by inhibition of β-catenin signaling in chondrocytes.Journal of orthopaedic translation · 2023Article
- Modulating p-AMPK/mTOR Pathway of Mitochondrial Dysfunction Caused by MTERF1 Abnormal Expression in Colorectal Cancer Cells.International journal of molecular sciences · 2022Article
- Metformin resistant MDA-MB-468 cells exhibit EMT-like phenotype and increased migration capacity.Molecular biology reports · 2022Article
- Riluzole regulates pancreatic cancer cell metabolism by suppressing the Wnt-β-catenin pathway.Scientific reports · 2022Article
- The role of AMPK-dependent pathways in cellular and molecular mechanisms of metformin: a new perspective for treatment and prevention of diseases.Inflammopharmacology · 2022Review
- Incidence and Survival Outcomes of Colorectal Cancer in Long-Term Metformin Users with Diabetes: A Population-Based Cohort Study Using a Common Data Model.Journal of personalized medicine · 2022Article
- Multi‑faceted role of cancer‑associated adipocytes in the tumor microenvironment (Review).Molecular medicine reports · 2021Review
- Evolution of β-catenin-independent Wnt-GSK3-mTOR signalling in regulation of energy metabolism in isoproterenol-induced cardiotoxicity model.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021Article
- Identification of novel DNA hypermethylation of the adenylate kinase 5 promoter in colorectal adenocarcinoma.Scientific reports · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metformin can suppress cell proliferation and viability by altering mitochondrial energy metabolism and by the activation of 5'-adenosine monophosphate-activated protein kinase (AMPK). The current study demonstrated that metformin-induced suppression of cell proliferation is further potentiated by AMPK-mediated suppression of β-catenin-dependent wingless-type (Wnt) signaling. Treatment with metformin reduced mitochondrial oxidative phosphorylation and glycolysis, leading to an energy imbalance that may induce AMPK phosphorylation in RKO cells. Metformin treatment also decreased β-catenin expression in the cytoplasm and nucleus. Active AMPK was revealed to be associated with β-catenin. The decrease in β-catenin expression was inhibited by proteosome inhibition through phosphorylation of β-catenin at serine 33/37. Given that nuclear translocation-associated phosphorylation of β-catenin at serine was maintained, the association of β-catenin with AMPK may sequester β-catenin in the cytoplasm and lead to proteosomal degradation. Furthermore, metformin-induced suppression of cell proliferation was partially recovered by AMPK inhibition, while metformin inhibited Wnt-mediated cell proliferation and β-catenin expression. The present results suggest that AMPK activation can suppress β-catenin-dependent Wnt signaling by cytoplasmic sequestering of β-catenin through AMPK, which further decreases cell proliferation in addition to metformin-induced mitochondrial dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.